<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Progress note - [REDACTED]</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Allergies</a></li><li><a href="#id2">REASON FOR VISIT</a></li><li><a href="#id3">Medications</a></li><li><a href="#id4">Social History</a></li><li><a href="#id5">Vital Signs</a></li><li><a href="#id6">Encounters</a></li><li><a href="#id7">Assessments</a></li><li><a href="#id8">Plan Of Treatment</a></li><li><a href="#id9">Progress Notes</a></li><li><a href="#id10">History and Physical Notes</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Allergies</a></h3><div><table width="100%" border="1"><thead><tr><th>Allergen (clinical drug ingredient)</th><th>Drug/Non Drug Allergy documented on EMR</th><th>Reaction</th><th>Allergy Type</th><th>Onset Date</th><th>Status</th></tr></thead><tbody><tr><td ID="allergy1"/><td>Haldol</td><td ID="reaction1">Tongue Swelling</td><td>Drug Allergy</td><td/><td>Active</td></tr><tr><td ID="allergy2"/><td>Thorazine</td><td ID="reaction2">Tongue Swelling</td><td>Drug Allergy</td><td/><td>Active</td></tr></tbody></table></div><h3><a name="id2" href="#toc">REASON FOR VISIT</a></h3><div>3 month f/u, Needs a closer podiatrist</div><h3><a name="id3" href="#toc">Medications</a></h3><div><table width="100%" border="1"><thead><tr><th>Medication</th><th>SIG (Take, Route, Frequency, Duration)</th><th>Notes</th><th>Start Date</th><th>End Date</th><th>Status</th></tr></thead><tbody><tr><td ID="medication1">Losartan Potassium 50 MG</td><td ID="instruction1">1 tablet Orally Once a day</td><td/><td/><td/><td>Not-Taking</td></tr><tr><td ID="medication2">Allopurinol 100 MG</td><td ID="instruction2">1 tablet Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication3">Ferrous Gluconate 324 (38 Fe) MG</td><td ID="instruction3">1 tablet Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication4">Ventolin HFA 108 (90 Base) MCG/ACT</td><td ID="instruction4"> Inhalation</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication5">Fleet Enema 7-19 GM/118ML</td><td ID="instruction5">as directed Rectal Once a day for 2 days</td><td/><td/><td/><td>Not-Taking</td></tr><tr><td ID="medication6">Gabapentin 300 MG</td><td ID="instruction6">1 capsule Orally Three times a day for 100 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication7">Bumetanide 0.5 MG</td><td ID="instruction7">1 tablet Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication8">Aspirin 81 MG</td><td ID="instruction8">1 tablet Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication9">Metoprolol Succinate ER 100 MG</td><td ID="instruction9">1 tablet Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication10">Atorvastatin Calcium 80 MG</td><td ID="instruction10">1 tablet Orally Once a day for 100 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication11">metFORMIN HCl 500 MG</td><td ID="instruction11">1 tablet with a meal Orally Twice a day</td><td/><td/><td/><td>Active</td></tr></tbody></table></div><h3><a name="id4" href="#toc">Social History</a></h3><div><span class="content_span">Tobacco Use:</span><table width="100%" border="1"><thead><tr><th>Social History Observation</th><th>Description</th><th>Date</th></tr></thead><tbody><tr><td ID="smokingStatus1">Details (start date - stop date)</td><td>Never Smoker</td><td>NA - NA</td></tr></tbody></table><span class="content_span">Sex Assigned At Birth:</span><table width="100%" border="1"><thead><tr><th>Social History Observation</th><th>Description</th></tr></thead><tbody><tr><td ID="BirthSexInfo">Sex Assigned At Birth</td><td>Male</td></tr></tbody></table><span class="content_span">Tobacco Control (Standard)</span><table ID="socialhistorynotes" width="100%" border="1"><thead><tr><th>Question</th><th>Answer</th><th>Notes</th></tr></thead><tbody><tr><td>Tobacco use:</td><td>Nonsmoker</td><td/></tr></tbody></table></div><h3><a name="id5" href="#toc">Vital Signs</a></h3><div><table width="100%" border="1"><tbody><tr><th ID="vital1">Temperature</th><td>97.3 degrees Fahrenheit</td><td>[REDACTED]</td></tr><tr><th ID="vital2">Blood pressure systolic</th><td>117 mm Hg</td><td>[REDACTED]</td></tr><tr><th ID="vital3">Blood pressure diastolic</th><td>70 mm Hg</td><td>[REDACTED]</td></tr><tr><th ID="vital4">Heart Rate</th><td>96 /min</td><td>[REDACTED]</td></tr><tr><th ID="vital5">Respiratory Rate</th><td>16 /min</td><td>[REDACTED]</td></tr><tr><th ID="vital6">Height</th><td>5'7" in</td><td>[REDACTED]</td></tr><tr><th ID="vital7">Weight</th><td>157 lbs</td><td>[REDACTED]</td></tr><tr><th ID="vital8">BMI</th><td>24.59 kg/m2</td><td>[REDACTED]</td></tr><tr><th ID="vital9">Oximetry</th><td>99 %</td><td>[REDACTED]</td></tr><tr><th ID="vital10">Height-cm</th><td>170.18 cm</td><td>[REDACTED]</td></tr><tr><th ID="vital11">Weight-kg</th><td>71.21 kg</td><td>[REDACTED]</td></tr></tbody></table></div><h3><a name="id6" href="#toc">Encounters</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter</th><th>Location</th><th>Date</th><th>Provider</th><th>Diagnosis</th></tr></thead><tbody><tr><td>MCM FT Lauderdale Galt Ocean</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Chronic combined systolic and diastolic congestive heart failure I50.42 ; Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease I13.0 ; Type 2 diabetes mellitus with diabetic chronic kidney disease E11.22 ; Chronic kidney disease, stage 3a N18.31 ; Type 2 diabetes mellitus with diabetic polyneuropathy, without long-term current use of insulin E11.42 ; Type 2 diabetes mellitus with other specified complication, without long-term current use of insulin E11.69 ; Chronic atrial fibrillation I48.20 ; Presence of Watchman left atrial appendage closure device Z95.818 ; HISTORY OF VENTRICULAR TACHYCARDIA Z86.79 ; Presence of biventricular implantable cardioverter-defibrillator (ICD) Z95.810 ; History of cardiac radiofrequency ablation Z98.890 ; Coronary artery disease involving native coronary artery of native heart without angina pectoris I25.10 ; S/P coronary artery stent placement Z95.5 ; Ischemic cardiomyopathy I25.5 ; Hyperlipidemia, unspecified hyperlipidemia type E78.5 ; Anemia in chronic kidney disease D63.1 ; Centrilobular emphysema J43.2 ; Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene, without long-term current use of insulin E11.51 ; HISTORY OF GOUT Z87.39 ; Schizophrenia, unspecified type F20.9 ; SECONDARY HYPERPARATHYROIDISM, RENAL N25.81 ; HISTORY OF SUBSTANCE ABUSE F19.11 ; Lung fibrosis J84.10 and Body mass index [BMI] 24.0-24.9, adult Z68.24</td></tr></tbody></table></div><h3><a name="id7" href="#toc">Assessments</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter Date</th><th>Diagnosis (ICD Code)</th><th>Assessment Notes</th><th>Treatment Notes</th><th>Treatment Clinical Notes</th></tr></thead><tbody><tr><td ID="ref1">[REDACTED]</td><td>Chronic combined systolic and diastolic congestive heart failure (ICD-10 - I50.42)</td><td/><td/><td/></tr><tr><td ID="ref2">[REDACTED]</td><td>Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease (ICD-10 - I13.0)</td><td/><td>Patient instructed to only take blood pressure medications once a day, and hold his medication if his systolic blood pressure is less than 100. Home Care RN for monitoring.</td><td/></tr><tr><td ID="ref3">[REDACTED]</td><td>Type 2 diabetes mellitus with diabetic chronic kidney disease (ICD-10 - E11.22)</td><td/><td>Continue diabetic management, monitor labs.</td><td/></tr><tr><td ID="ref4">[REDACTED]</td><td>Chronic kidney disease, stage 3a (ICD-10 - N18.31)</td><td/><td>Avoid nephrotoxic agents, Monitor renal function</td><td/></tr><tr><td ID="ref5">[REDACTED]</td><td>Type 2 diabetes mellitus with diabetic polyneuropathy, without long-term current use of insulin (ICD-10 - E11.42)</td><td/><td>Continue diabetic management, monitor labs.</td><td/></tr><tr><td ID="ref6">[REDACTED]</td><td>Type 2 diabetes mellitus with other specified complication, without long-term current use of insulin (ICD-10 - E11.69)</td><td/><td>Diabetes with hyperlipidemia.</td><td>Diabetes with hyperlipidemia.</td></tr><tr><td ID="ref7">[REDACTED]</td><td>Chronic atrial fibrillation (ICD-10 - I48.20)</td><td/><td>Continue medication therapy, follow up with cardiology. Anticoagulation not indicated due to Watchman procedure</td><td/></tr><tr><td ID="ref8">[REDACTED]</td><td>Presence of Watchman left atrial appendage closure device (ICD-10 - Z95.818)</td><td/><td>Patient s/p closure of left atrial appendage, anticoagulation no longer required.</td><td/></tr><tr><td ID="ref9">[REDACTED]</td><td>HISTORY OF VENTRICULAR TACHYCARDIA (ICD-10 - Z86.79)</td><td/><td>S/p cardiac ablation with ICD in place, follow up with cardiology/EPS</td><td/></tr><tr><td ID="ref10">[REDACTED]</td><td>Presence of biventricular implantable cardioverter-defibrillator (ICD) (ICD-10 - Z95.810)</td><td/><td>Follow up with cardiology/EPS</td><td/></tr><tr><td ID="ref11">[REDACTED]</td><td>History of cardiac radiofrequency ablation (ICD-10 - Z98.890)</td><td/><td>Follow up with cardiology/EPS</td><td/></tr><tr><td ID="ref12">[REDACTED]</td><td>Coronary artery disease involving native coronary artery of native heart without angina pectoris (ICD-10 - I25.10)</td><td/><td>Continue medication managment, follow up with cardiology</td><td/></tr><tr><td ID="ref13">[REDACTED]</td><td>S/P coronary artery stent placement (ICD-10 - Z95.5)</td><td/><td>Continue medication managment, follow up with cardiology</td><td/></tr><tr><td ID="ref14">[REDACTED]</td><td>Ischemic cardiomyopathy (ICD-10 - I25.5)</td><td/><td>Continue medication managment, follow up with cardiology</td><td/></tr><tr><td ID="ref15">[REDACTED]</td><td>Hyperlipidemia, unspecified hyperlipidemia type (ICD-10 - E78.5)</td><td/><td/><td/></tr><tr><td ID="ref16">[REDACTED]</td><td>Anemia in chronic kidney disease (ICD-10 - D63.1)</td><td/><td>Monitor CBC, being treated with iron infusions by hematology</td><td/></tr><tr><td ID="ref17">[REDACTED]</td><td>Centrilobular emphysema (ICD-10 - J43.2)</td><td/><td>Continue use of inhaler PRN</td><td/></tr><tr><td ID="ref18">[REDACTED]</td><td>Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene, without long-term current use of insulin (ICD-10 - E11.51)</td><td/><td>Continue diabetic management, monitor labs.</td><td>Continue aspirin, statin therapy and blood pressure control</td></tr><tr><td ID="ref19">[REDACTED]</td><td>HISTORY OF GOUT (ICD-10 - Z87.39)</td><td/><td/><td/></tr><tr><td ID="ref20">[REDACTED]</td><td>Schizophrenia, unspecified type (ICD-10 - F20.9)</td><td/><td>Condition currently stable, not requiring treatment. Continue to monitor.</td><td/></tr><tr><td ID="ref21">[REDACTED]</td><td>SECONDARY HYPERPARATHYROIDISM, RENAL (ICD-10 - N25.81)</td><td/><td>PTH level elevated with normal calcium level, continue to monitor</td><td/></tr><tr><td ID="ref22">[REDACTED]</td><td>HISTORY OF SUBSTANCE ABUSE (ICD-10 - F19.11)</td><td/><td>Remains abstinent from drug use</td><td/></tr><tr><td ID="ref23">[REDACTED]</td><td>Lung fibrosis (ICD-10 - J84.10)</td><td/><td>Fibrosis of lungs noted on prior CT scan. Patient is asymptomatic, and treatment not indicated.</td><td/></tr><tr><td ID="ref24">[REDACTED]</td><td>Body mass index [BMI] 24.0-24.9, adult (ICD-10 - Z68.24)</td><td/><td/><td/></tr></tbody></table></div><h3><a name="id8" href="#toc">Plan Of Treatment</a></h3><div><span class="content_span">Medication</span><table width="100%" border="1"><thead><tr><th>Medication Name</th><th>Sig</th><th>Start Date</th><th>Stop Date</th><th>Notes</th></tr></thead><tbody><tr><td ID="potMeds1">Allopurinol 100 MG</td><td>1 tablet Orally Once a day</td><td/><td/><td/></tr><tr><td ID="potMeds2">Ferrous Gluconate 324 (38 Fe) MG</td><td>1 tablet Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds3">Ventolin HFA 108 (90 Base) MCG/ACT</td><td> Inhalation</td><td/><td/><td/></tr><tr><td ID="potMeds4">Gabapentin 300 MG</td><td>1 capsule Orally Three times a day for 100 days</td><td/><td/><td/></tr><tr><td ID="potMeds5">Bumetanide 0.5 MG</td><td>1 tablet Orally Once a day</td><td/><td/><td/></tr><tr><td ID="potMeds6">Aspirin 81 MG</td><td>1 tablet Orally Once a day</td><td/><td/><td/></tr><tr><td ID="potMeds7">Metoprolol Succinate ER 100 MG</td><td>1 tablet Orally Once a day</td><td/><td/><td/></tr><tr><td ID="potMeds8">Atorvastatin Calcium 80 MG</td><td>1 tablet Orally Once a day for 100 days</td><td/><td/><td/></tr><tr><td ID="potMeds9">metFORMIN HCl 500 MG</td><td>1 tablet with a meal Orally Twice a day</td><td/><td/><td/></tr></tbody></table><span class="content_span">Treatment Notes</span><table width="100%" border="1"><thead><tr><th>Assessment</th><th>Notes</th></tr></thead><tbody><tr><td ID="instructionpot1">Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease</td><td>Patient instructed to only take blood pressure medications once a day, and hold his medication if his systolic blood pressure is less than 100. Home Care RN for monitoring.</td></tr><tr><td ID="instructionpot2">Type 2 diabetes mellitus with diabetic chronic kidney disease</td><td>Continue diabetic management, monitor labs.</td></tr><tr><td ID="instructionpot3">Chronic kidney disease, stage 3a</td><td>Avoid nephrotoxic agents, Monitor renal function</td></tr><tr><td ID="instructionpot4">Type 2 diabetes mellitus with diabetic polyneuropathy, without long-term current use of insulin</td><td>Continue diabetic management, monitor labs.</td></tr><tr><td ID="instructionpot5">Type 2 diabetes mellitus with other specified complication, without long-term current use of insulin</td><td>Diabetes with hyperlipidemia.</td></tr><tr><td ID="instructionpot6">Chronic atrial fibrillation</td><td>Continue medication therapy, follow up with cardiology. Anticoagulation not indicated due to Watchman procedure</td></tr><tr><td ID="instructionpot7">Presence of Watchman left atrial appendage closure device</td><td>Patient s/p closure of left atrial appendage, anticoagulation no longer required.</td></tr><tr><td ID="instructionpot8">HISTORY OF VENTRICULAR TACHYCARDIA</td><td>S/p cardiac ablation with ICD in place, follow up with cardiology/EPS</td></tr><tr><td ID="instructionpot9">Presence of biventricular implantable cardioverter-defibrillator (ICD)</td><td>Follow up with cardiology/EPS</td></tr><tr><td ID="instructionpot10">History of cardiac radiofrequency ablation</td><td>Follow up with cardiology/EPS</td></tr><tr><td ID="instructionpot11">Coronary artery disease involving native coronary artery of native heart without angina pectoris</td><td>Continue medication managment, follow up with cardiology</td></tr><tr><td ID="instructionpot12">S/P coronary artery stent placement</td><td>Continue medication managment, follow up with cardiology</td></tr><tr><td ID="instructionpot13">Ischemic cardiomyopathy</td><td>Continue medication managment, follow up with cardiology</td></tr><tr><td ID="instructionpot14">Anemia in chronic kidney disease</td><td>Monitor CBC, being treated with iron infusions by hematology</td></tr><tr><td ID="instructionpot15">Centrilobular emphysema</td><td>Continue use of inhaler PRN</td></tr><tr><td ID="instructionpot16">Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene, without long-term current use of insulin</td><td>Continue diabetic management, monitor labs.</td></tr><tr><td ID="instructionpot17">Schizophrenia, unspecified type</td><td>Condition currently stable, not requiring treatment. Continue to monitor.</td></tr><tr><td ID="instructionpot18">SECONDARY HYPERPARATHYROIDISM, RENAL</td><td>PTH level elevated with normal calcium level, continue to monitor</td></tr><tr><td ID="instructionpot19">HISTORY OF SUBSTANCE ABUSE</td><td>Remains abstinent from drug use</td></tr><tr><td ID="instructionpot20">Lung fibrosis</td><td>Fibrosis of lungs noted on prior CT scan. Patient is asymptomatic, and treatment not indicated.</td></tr></tbody></table><span class="content_span">Future Test</span><table width="100%" border="1"><thead><tr><th>Test Name</th><th>Order Date</th></tr></thead><tbody><tr><td ID="futureTest1">Vitamin B12 and Folate-000810</td><td>[REDACTED]</td></tr><tr><td ID="futureTest2">Iron and TIBC-001321</td><td>[REDACTED]</td></tr><tr><td ID="futureTest3">Hemoglobin A1c-001453</td><td>[REDACTED]</td></tr><tr><td ID="futureTest4">Ferritin-004598</td><td>[REDACTED]</td></tr><tr><td ID="futureTest5">CBC With Differential/Platelet-005009</td><td>[REDACTED]</td></tr><tr><td ID="futureTest6">T4 and TSH-024026</td><td>[REDACTED]</td></tr><tr><td ID="futureTest7">Vitamin D, 25-Hydroxy-081950</td><td>[REDACTED]</td></tr><tr><td ID="futureTest8">Fructosamine-100800</td><td>[REDACTED]</td></tr><tr><td ID="futureTest9">Albumin/Creatinine Ratio,Urine-140285</td><td>[REDACTED]</td></tr><tr><td ID="futureTest10">Lipid Panel With LDL/HDL Ratio-235010</td><td>[REDACTED]</td></tr></tbody></table><span class="content_span">Next Appt</span><table width="100%" border="1"><thead><tr><th>Details</th></tr></thead><tbody><tr><td ID="nextAppt">Follow Up: 3 Months,prn, Reason: </td></tr><tr><td ID="futureAppt1">Provider Name:[REDACTED], [REDACTED] 09:20:00 AM, [REDACTED][REDACTED], [REDACTED]</td></tr><tr><td ID="futureAppt2">Provider Name:[REDACTED], [REDACTED] 11:00:00 AM, [REDACTED][REDACTED], [REDACTED]</td></tr></tbody></table></div><h3><a name="id9" href="#toc">Progress Notes</a></h3><div><ul><li><table width="99%" border="0" cellspacing="0" cellpadding="0"><thead><tr><td><content>[REDACTED] <span class="bold">DOB:</span> [REDACTED] ([REDACTED] M) <span class="bold">Acc No.</span> 284721 <span class="bold">DOS:</span> [REDACTED]</content></td></tr></thead><tbody><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td align="right" colspan="2"><span class="bold"/></td></tr><tr><td align="left"><span class="bold">Patient: </span>[REDACTED]<br/><span class="bold">Account Number: </span>284721</td><td align="right"><span class="bold">Provider: </span>[REDACTED], MD</td></tr><tr><td align="left"/></tr><tr><td align="left"><span class="bold">DOB: </span>[REDACTED]<span class="bold">   Age: </span>78 Y<span class="bold">   Sex: </span>Male</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td><span class="bold">Phone: </span>[REDACTED]</td></tr><tr><td colspan="2"><span class="bold">Address: </span>[REDACTED][REDACTED]</td></tr></tbody></table></li></ul><br/><content><span class="bold">Subjective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Chief Complaints:</span></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td>   3 month f/uNeeds a closer podiatrist</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">HPI: </span><br/>   <span class="Underline">Routine F/U</span>: <br/>       [REDACTED] is a [REDACTED] male with type 2 diabetes with diabetic neuropathy, hyperlipidemia, hypertension, coronary artery disease with history of stent placement, ischemic cardiomyopathy with chronic heart failure, atrial fibrillation s/p watchman procedure, history of ventricular tachycardia s/p cardiac ablation and ICD placement, chronic anemia, chronic kidney disease and schizophrenia.<br/><br/>He presents for follow up.<br/><br/>He has no complaints [REDACTED], and reports an upcoming appointment with his eye doctor.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">ROS:</span> <br/>   <span class="Underline">General ROS</span>: <br/>      General / Constitutional: no fever, chills, weight loss or night sweats. Ophthalmologic: No visual disturbance.   <br/>   <span class="Underline">Respiratory</span>: <br/>      Patient denies Shortness of breath, cough, chest congestion or sputum production.   <br/>   <span class="Underline">Cardiovascular</span>: <br/>      Patient denies Chest pain, palpitations, lightheadedness, exercise intolerance or weakness.   <br/>   <span class="Underline">Gastrointestinal</span>: <br/>      Patient denies Nausea, vomiting, change in bowel habits, diarrhea or constipation, no blood in stool.   <br/>   <span class="Underline">Genitourinary</span>: <br/>      Patient denies Urinary symptoms, urgency, frequency, difficulty with flow of urine, blood in urine.   <br/>   <span class="Underline">Musculoskeletal</span>: <br/>      Patient denies joint pains or stiffness, muscle aches, or leg swelling.   <br/>   <span class="Underline">Peripheral Vascular</span>: <br/>      Patient denies Poor circulation, leg pains or cramps, leg ulcers or skin discoloration.   <br/>   <span class="Underline">Skin</span>: <br/>      Patient denies Skin lesions, masses or rash.   <br/>   <span class="Underline">Neurologic</span>: <br/>      Patient denies Dizziness, weakness, decreased strength, confusion or memory loss. Patient complains of tingling in feet and hands.   <br/>   <span class="Underline">Psychiatric</span>: <br/>      Patient denies Depression, anxiety or suicidal or homicidal ideation.   <br/>   </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medical History:</span> </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Surgical History:</span> pacemaker 2020stent 2020</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Hospitalization/Major Diagnostic Procedure:</span> Denies Past Hospitalization</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Family History:</span> Father: deceased, heart disease. Mother: deceased, heart disease, hypertension, diabetes. 2 brother(s) . . </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Social History:</span> <br/>   <span class="Underline">Tobacco Use:</span> Tobacco Control (Standard) Tobacco use: Nonsmoker. <br/>   <span class="Underline">Drugs/Alcohol:</span> Drugs Have you used drugs other than those for medical reasons in the past 12 months? No. Caffeine Intake: none. Do you drink alcohol?: No. <br/>   <span class="Underline">Miscellaneous:</span> Exercise: no. </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medications:</span> TakingAspirin 81 MG Tablet Delayed Release 1 tablet Orally Once a day Atorvastatin Calcium 80 MG Tablet 1 tablet Orally Once a day Bumetanide 0.5 MG Tablet 1 tablet Orally Once a day Ferrous Gluconate 324 (38 Fe) MG Tablet 1 tablet Orally Once a day Gabapentin 300 MG Capsule 1 capsule Orally Three times a day metFORMIN HCl 500 MG Tablet 1 tablet with a meal Orally Twice a day Metoprolol Succinate ER 100 MG Tablet Extended Release 24 Hour 1 tablet Orally Once a day Ventolin HFA 108 (90 Base) MCG/ACT Aerosol Solution  Inhalation  Taking Aspirin 81 MG Tablet Delayed Release 1 tablet Orally Once a day Taking Atorvastatin Calcium 80 MG Tablet 1 tablet Orally Once a day Taking Bumetanide 0.5 MG Tablet 1 tablet Orally Once a day Taking Ferrous Gluconate 324 (38 Fe) MG Tablet 1 tablet Orally Once a day Taking Gabapentin 300 MG Capsule 1 capsule Orally Three times a day Taking metFORMIN HCl 500 MG Tablet 1 tablet with a meal Orally Twice a day Taking Metoprolol Succinate ER 100 MG Tablet Extended Release 24 Hour 1 tablet Orally Once a day Taking Ventolin HFA 108 (90 Base) MCG/ACT Aerosol Solution  Inhalation  Not-TakingAllopurinol 100 MG Tablet 1 tablet Orally Once a day , Notes to Pharmacist: PRNFleet Enema 7-19 GM/118ML Enema as directed Rectal Once a day Losartan Potassium 50 MG Tablet 1 tablet Orally Once a day Medication List reviewed and reconciled with the patientNot-Taking Allopurinol 100 MG Tablet 1 tablet Orally Once a day , Notes to Pharmacist: PRNNot-Taking Fleet Enema 7-19 GM/118ML Enema as directed Rectal Once a day Not-Taking Losartan Potassium 50 MG Tablet 1 tablet Orally Once a day Medication List reviewed and reconciled with the patient</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Allergies:</span> Thorazine: Tongue Swelling - Allergy - Criticality HighHaldol: Tongue Swelling - Allergy - Criticality Highno[Allergies Verified]</td></tr></tbody></table></li></ul><br/><content><span class="bold">Objective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Vitals:</span> Ht: 5'7", Wt: 157 lbs, Wt-kg: 71.21 kg, BMI: 24.59 Index, BP: 117/70 mm Hg, HR: 96 /min, Temp: 97.3 F, RR: 16 /min, Oxygen sat %: 99 %, Pain scale: 0 1-10, Body Surface Area: 1.83, Ht-cm: 170.18 cm.<br/></td></tr></tbody></table></li></ul><ul><li><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><span class="bold">   Past Orders:</span></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:CBC With Differential/Platelet-005009</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Collection Time</td><td align="left">08:07 AM</td><td align="left">09:41 AM</td></tr><tr><td align="left">Order Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">WBC</td><td align="left">4.0<br/>(Ref Range: 3.4-10.8 x10E3/uL)</td><td align="left">4.7<br/>(Ref Range: 3.4-10.8 x10E3/uL)</td></tr><tr><td align="left">RBC</td><td class="bold" align="left">3.10    L<br/>(Ref Range: 4.14-5.80 x10E6/uL)</td><td class="bold" align="left">3.23    L<br/>(Ref Range: 4.14-5.80 x10E6/uL)</td></tr><tr><td align="left">Hemoglobin</td><td class="bold" align="left">9.8    L<br/>(Ref Range: 13.0-17.7 g/dL)</td><td class="bold" align="left">9.8    L<br/>(Ref Range: 13.0-17.7 g/dL)</td></tr><tr><td align="left">Hematocrit</td><td class="bold" align="left">29.8    L<br/>(Ref Range: 37.5-51.0 %)</td><td class="bold" align="left">31.1    L<br/>(Ref Range: 37.5-51.0 %)</td></tr><tr><td align="left">MCV</td><td align="left">96<br/>(Ref Range: 79-97 fL)</td><td align="left">96<br/>(Ref Range: 79-97 fL)</td></tr><tr><td align="left">MCH</td><td align="left">31.6<br/>(Ref Range: 26.6-33.0 pg)</td><td align="left">30.3<br/>(Ref Range: 26.6-33.0 pg)</td></tr><tr><td align="left">MCHC</td><td align="left">32.9<br/>(Ref Range: 31.5-35.7 g/dL)</td><td align="left">31.5<br/>(Ref Range: 31.5-35.7 g/dL)</td></tr><tr><td align="left">RDW</td><td align="left">13.2<br/>(Ref Range: 11.6-15.4 %)</td><td align="left">14.0<br/>(Ref Range: 11.6-15.4 %)</td></tr><tr><td align="left">Platelets</td><td align="left">181<br/>(Ref Range: 150-450 x10E3/uL)</td><td align="left">168<br/>(Ref Range: 150-450 x10E3/uL)</td></tr><tr><td align="left">Neutrophils</td><td align="left">61<br/>(Ref Range: Not Estab. %)</td><td align="left">68<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Lymphs</td><td align="left">25<br/>(Ref Range: Not Estab. %)</td><td align="left">20<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Monocytes</td><td align="left">11<br/>(Ref Range: Not Estab. %)</td><td align="left">9<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Eos</td><td align="left">2<br/>(Ref Range: Not Estab. %)</td><td align="left">2<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Basos</td><td align="left">1<br/>(Ref Range: Not Estab. %)</td><td align="left">1<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Neutrophils (Absolute)</td><td align="left">2.4<br/>(Ref Range: 1.4-7.0 x10E3/uL)</td><td align="left">3.2<br/>(Ref Range: 1.4-7.0 x10E3/uL)</td></tr><tr><td align="left">Lymphs (Absolute)</td><td align="left">1.0<br/>(Ref Range: 0.7-3.1 x10E3/uL)</td><td align="left">0.9<br/>(Ref Range: 0.7-3.1 x10E3/uL)</td></tr><tr><td align="left">Monocytes(Absolute)</td><td align="left">0.5<br/>(Ref Range: 0.1-0.9 x10E3/uL)</td><td align="left">0.4<br/>(Ref Range: 0.1-0.9 x10E3/uL)</td></tr><tr><td align="left">Eos (Absolute)</td><td align="left">0.1<br/>(Ref Range: 0.0-0.4 x10E3/uL)</td><td align="left">0.1<br/>(Ref Range: 0.0-0.4 x10E3/uL)</td></tr><tr><td align="left">Baso (Absolute)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.2 x10E3/uL)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.2 x10E3/uL)</td></tr><tr><td align="left">Immature Granulocytes</td><td align="left">0<br/>(Ref Range: Not Estab. %)</td><td align="left">0<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Immature Grans (Abs)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.1 x10E3/uL)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.1 x10E3/uL)</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Comp. Metabolic Panel (14)-322000</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Collection Time</td><td align="left">08:07 AM</td><td align="left">09:41 AM</td></tr><tr><td align="left">Order Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Glucose</td><td class="bold" align="left">126    H<br/>(Ref Range: 70-99 mg/dL)</td><td align="left">95<br/>(Ref Range: 70-99 mg/dL)</td></tr><tr><td align="left">BUN</td><td class="bold" align="left">38    H<br/>(Ref Range: 8-27 mg/dL)</td><td class="bold" align="left">41    H<br/>(Ref Range: 8-27 mg/dL)</td></tr><tr><td align="left">Sodium</td><td align="left">139<br/>(Ref Range: 134-144 mmol/L)</td><td align="left">139<br/>(Ref Range: 134-144 mmol/L)</td></tr><tr><td align="left">BUN/Creatinine Ratio</td><td align="left">24<br/>(Ref Range: 10-24)</td><td class="bold" align="left">27    H<br/>(Ref Range: 10-24)</td></tr><tr><td align="left">Chloride</td><td align="left">97<br/>(Ref Range: 96-106 mmol/L)</td><td align="left">99<br/>(Ref Range: 96-106 mmol/L)</td></tr><tr><td align="left">Potassium</td><td align="left">4.6<br/>(Ref Range: 3.5-5.2 mmol/L)</td><td align="left">4.8<br/>(Ref Range: 3.5-5.2 mmol/L)</td></tr><tr><td align="left">Calcium</td><td align="left">9.3<br/>(Ref Range: 8.6-10.2 mg/dL)</td><td align="left">9.2<br/>(Ref Range: 8.6-10.2 mg/dL)</td></tr><tr><td align="left">Protein, Total</td><td align="left">7.5<br/>(Ref Range: 6.0-8.5 g/dL)</td><td align="left">7.5<br/>(Ref Range: 6.0-8.5 g/dL)</td></tr><tr><td align="left">Albumin</td><td align="left">4.6<br/>(Ref Range: 3.8-4.8 g/dL)</td><td align="left">4.6<br/>(Ref Range: 3.8-4.8 g/dL)</td></tr><tr><td align="left">Globulin, Total</td><td align="left">2.9<br/>(Ref Range: 1.5-4.5 g/dL)</td><td align="left">2.9<br/>(Ref Range: 1.5-4.5 g/dL)</td></tr><tr><td align="left">A/G Ratio</td><td align="left">NR<br/></td><td align="left">1.6<br/>(Ref Range: 1.2-2.2)</td></tr><tr><td align="left">Bilirubin, Total</td><td align="left">0.7<br/>(Ref Range: 0.0-1.2 mg/dL)</td><td align="left">0.6<br/>(Ref Range: 0.0-1.2 mg/dL)</td></tr><tr><td align="left">Alkaline Phosphatase</td><td align="left">71<br/>(Ref Range: 44-121 IU/L)</td><td align="left">69<br/>(Ref Range: 44-121 IU/L)</td></tr><tr><td align="left">AST (SGOT)</td><td align="left">14<br/>(Ref Range: 0-40 IU/L)</td><td align="left">13<br/>(Ref Range: 0-40 IU/L)</td></tr><tr><td align="left">ALT (SGPT)</td><td align="left">9<br/>(Ref Range: 0-44 IU/L)</td><td align="left">9<br/>(Ref Range: 0-44 IU/L)</td></tr><tr><td align="left">eGFR</td><td class="bold" align="left">44    L<br/>(Ref Range: &gt;59 mL/min/1.73)</td><td class="bold" align="left">46    L<br/>(Ref Range: &gt;59 mL/min/1.73)</td></tr><tr><td align="left">Creatinine</td><td class="bold" align="left">1.58    H<br/>(Ref Range: 0.76-1.27 mg/dL)</td><td class="bold" align="left">1.54    H<br/>(Ref Range: 0.76-1.27 mg/dL)</td></tr><tr><td align="left">Carbon Dioxide, Total</td><td align="left">28<br/>(Ref Range: 20-29 mmol/L)</td><td align="left">20<br/>(Ref Range: 20-29 mmol/L)</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Lipid Panel With LDL/HDL Ratio-235010</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Collection Time</td><td align="left">08:07 AM</td><td align="left">09:41 AM</td></tr><tr><td align="left">Order Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Cholesterol, Total</td><td align="left">149<br/>(Ref Range: 100-199 mg/dL)</td><td align="left">142<br/>(Ref Range: 100-199 mg/dL)</td></tr><tr><td align="left">Triglycerides</td><td align="left">78<br/>(Ref Range: 0-149 mg/dL)</td><td align="left">81<br/>(Ref Range: 0-149 mg/dL)</td></tr><tr><td align="left">HDL Cholesterol</td><td align="left">70<br/>(Ref Range: &gt;39 mg/dL)</td><td align="left">62<br/>(Ref Range: &gt;39 mg/dL)</td></tr><tr><td align="left">VLDL Cholesterol Cal</td><td align="left">15<br/>(Ref Range: 5-40 mg/dL)</td><td align="left">16<br/>(Ref Range: 5-40 mg/dL)</td></tr><tr><td align="left">LDL Chol Calc (NIH)</td><td align="left">64<br/>(Ref Range: 0-99 mg/dL)</td><td align="left">64<br/>(Ref Range: 0-99 mg/dL)</td></tr><tr><td align="left">LDL/HDL Ratio</td><td align="left">0.9<br/>(Ref Range: 0.0-3.6 ratio)</td><td align="left">1.0<br/>(Ref Range: 0.0-3.6 ratio)</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Hemoglobin A1c-001453</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Collection Time</td><td align="left">08:07 AM</td><td align="left">09:41 AM</td></tr><tr><td align="left">Order Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Hemoglobin A1c</td><td align="left">5.6<br/>(Ref Range: 4.8-5.6 %)</td><td align="left">5.5<br/>(Ref Range: 4.8-5.6 %)</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4">   <content class="Underline"><span class="bold">Lab:Uric Acid-001057 (Order Date - [REDACTED]) (Collection Date &amp; Time - [REDACTED] 08:07 AM)</span></content></td></tr><tr><td align="left">        </td><td align="left" colspan="2">Value</td><td align="left">Reference Range</td></tr><tr><td align="left">        Uric Acid</td><td align="left">8.6</td><td align="left">H</td><td align="left">3.8-8.4 - mg/dL</td></tr><tr><td colspan="4"><br/></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Albumin/Creatinine Ratio,Urine-140285</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Collection Time</td><td align="left">08:07 AM</td><td align="left">09:41 AM</td></tr><tr><td align="left">Order Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Creatinine, Urine</td><td align="left">73.7<br/>(Ref Range: Not Estab. mg/dL)</td><td align="left">154.6<br/>(Ref Range: Not Estab. mg/dL)</td></tr><tr><td align="left">Albumin, Urine</td><td align="left">8.4<br/>(Ref Range: Not Estab. ug/mL)</td><td align="left">10.5<br/>(Ref Range: Not Estab. ug/mL)</td></tr><tr><td align="left">Alb/Creat Ratio</td><td align="left">11<br/>(Ref Range: 0-29 mg/g creat)</td><td align="left">7<br/>(Ref Range: 0-29 mg/g creat)</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Urinalysis, Routine w/Rfx-346118</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Collection Time</td><td align="left">08:07 AM</td><td align="left">09:41 AM</td></tr><tr><td align="left">Order Date</td><td align="left">[REDACTED]</td><td align="left">[REDACTED]</td></tr><tr><td align="left">Specific Gravity</td><td align="left">1.013<br/>(Ref Range: 1.005-1.030)</td><td align="left">1.015<br/>(Ref Range: 1.005-1.030)</td></tr><tr><td align="left">pH</td><td align="left">6.0<br/>(Ref Range: 5.0-7.5)</td><td align="left">5.0<br/>(Ref Range: 5.0-7.5)</td></tr><tr><td align="left">Urine-Color</td><td align="left">Yellow<br/>(Ref Range: Yellow)</td><td align="left">Yellow<br/>(Ref Range: Yellow)</td></tr><tr><td align="left">Appearance</td><td align="left">Clear<br/>(Ref Range: Clear)</td><td align="left">Clear<br/>(Ref Range: Clear)</td></tr><tr><td align="left">WBC Esterase</td><td align="left">Negative<br/>(Ref Range: Negative)</td><td align="left">Negative<br/>(Ref Range: Negative)</td></tr><tr><td align="left">Protein</td><td align="left">Negative<br/>(Ref Range: Negative/Trace)</td><td align="left">Negative<br/>(Ref Range: Negative/Trace)</td></tr><tr><td align="left">Glucose</td><td align="left">Negative<br/>(Ref Range: Negative)</td><td align="left">Negative<br/>(Ref Range: Negative)</td></tr><tr><td align="left">Ketones</td><td align="left">Negative<br/>(Ref Range: Negative)</td><td align="left">Negative<br/>(Ref Range: Negative)</td></tr><tr><td align="left">Occult Blood</td><td align="left">Negative<br/>(Ref Range: Negative)</td><td align="left">Negative<br/>(Ref Range: Negative)</td></tr><tr><td align="left">Bilirubin</td><td align="left">Negative<br/>(Ref Range: Negative)</td><td align="left">Negative<br/>(Ref Range: Negative)</td></tr><tr><td align="left">Urobilinogen,Semi-Qn</td><td align="left">1.0<br/>(Ref Range: 0.2-1.0 mg/dL)</td><td align="left">1.0<br/>(Ref Range: 0.2-1.0 mg/dL)</td></tr><tr><td align="left">Nitrite, Urine</td><td align="left">Negative<br/>(Ref Range: Negative)</td><td align="left">Negative<br/>(Ref Range: Negative)</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4">   <content class="Underline"><span class="bold">Lab:Intact PTH (Includes Calcium)-500692 (Order Date - [REDACTED]) (Collection Date &amp; Time - [REDACTED])</span></content></td></tr><tr><td align="left">        </td><td align="left" colspan="2">Value</td><td align="left">Reference Range</td></tr><tr><td align="left">        Calcium, Serum</td><td align="left">9.4</td><td align="left"/><td align="left"> - mg/dL</td></tr><tr><td align="left">        PTH (Intact Assay)</td><td align="left">138</td><td align="left">H</td><td align="left"> - pg/mL</td></tr><tr><td colspan="4"><br/></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Physical Examination:</span> <br/>   <span class="Underline">GENERAL</span>: <br/>      - well-appearing, well-developed, no acute distress. <br/>   <span class="Underline">HEENT</span>: <br/>      - PERRLA, EOMI, no palor or icterus. <br/>   <span class="Underline">NECK</span>: <br/>      - no JVD, no lymphadenopathy, no thyroidomegaly, no carotid bruit. <br/>   <span class="Underline">Chest</span>: <br/>      - Symmetric with normal chest wall movement. <br/>   <span class="Underline">HEART</span>: <br/>      - Regular rhytm, S1S2 normal. <br/>   <span class="Underline">ABDOMEN</span>: <br/>      - Soft, non tender, not disended, BS +, no organomegaly. <br/>   <span class="Underline">NEUROLOGY</span>: <br/>      - Conscious, AAO x 3, no new focal deficits. <br/>   <span class="Underline">EXTREMITIES</span>: <br/>      - No cyanosis, clubbing or edema. <br/>   <span class="Underline">SKIN</span>: <br/>      - normal turgor and texture. <br/>   </td></tr></tbody></table></li></ul><br/><content><span class="bold">Assessment:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Assessment: </span></td></tr><tr><td/></tr><tr><td>1. Chronic combined systolic and diastolic congestive heart failure - I50.42 (Primary)   2. Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease - I13.0   3. Type 2 diabetes mellitus with diabetic chronic kidney disease - E11.22   4. Chronic kidney disease, stage 3a - N18.31   5. Type 2 diabetes mellitus with diabetic polyneuropathy, without long-term current use of insulin - E11.42   6. Type 2 diabetes mellitus with other specified complication, without long-term current use of insulin - E11.69   7. Chronic atrial fibrillation - I48.20   8. Presence of Watchman left atrial appendage closure device - Z95.818   9. HISTORY OF VENTRICULAR TACHYCARDIA - Z86.79   10. Presence of biventricular implantable cardioverter-defibrillator (ICD) - Z95.810   11. History of cardiac radiofrequency ablation - Z98.890   12. Coronary artery disease involving native coronary artery of native heart without angina pectoris - I25.10   13. S/P coronary artery stent placement - Z95.5   14. Ischemic cardiomyopathy - I25.5   15. Hyperlipidemia, unspecified hyperlipidemia type - E78.5   16. Anemia in chronic kidney disease - D63.1   17. Centrilobular emphysema - J43.2   18. Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene, without long-term current use of insulin - E11.51   19. HISTORY OF GOUT - Z87.39   20. Schizophrenia, unspecified type - F20.9   21. SECONDARY HYPERPARATHYROIDISM, RENAL - N25.81   22. HISTORY OF SUBSTANCE ABUSE - F19.11   23. Lung fibrosis - J84.10   24. Body mass index [BMI] 24.0-24.9, adult - Z68.24   </td></tr></tbody></table></li></ul><br/><content><span class="bold">Plan:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Treatment:</span></td></tr><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">1. Chronic combined systolic and diastolic congestive heart failure</span> <br/>Continue Bumetanide Tablet, 0.5 MG, 1 tablet, Orally, Once a day.  <br/>     <span class="Underline">LAB: T4 and TSH-024026 (Ordered for [REDACTED])</span></td></tr><tr><td/></tr><tr><td><span class="bold">2. Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease</span> <br/>Continue Metoprolol Succinate ER Tablet Extended Release 24 Hour, 100 MG, 1 tablet, Orally, Once a day.  <br/>Notes: Patient instructed to only take blood pressure medications once a day, and hold his medication if his systolic blood pressure is less than 100. Home Care RN for monitoring.  </td></tr><tr><td/></tr><tr><td><span class="bold">3. Type 2 diabetes mellitus with diabetic chronic kidney disease</span> <br/>     <span class="Underline">LAB: Albumin/Creatinine Ratio,Urine-140285 (Ordered for [REDACTED])</span><br/>     <span class="Underline">LAB: CBC With Differential/Platelet-005009 (Ordered for [REDACTED])</span><br/>     <span class="Underline">LAB: Fructosamine-100800 (Ordered for [REDACTED])</span><br/>     <span class="Underline">LAB: Hemoglobin A1c-001453 (Ordered for [REDACTED])</span><br/>Notes: Continue diabetic management, monitor labs.  </td></tr><tr><td/></tr><tr><td><span class="bold">4. Chronic kidney disease, stage 3a</span> <br/>     <span class="Underline">LAB: Vitamin D, 25-Hydroxy-081950 (Ordered for [REDACTED])</span><br/>Notes: Avoid nephrotoxic agents, Monitor renal function  </td></tr><tr><td/></tr><tr><td><span class="bold">5. Type 2 diabetes mellitus with diabetic polyneuropathy, without long-term current use of insulin</span> <br/>Continue Gabapentin Capsule, 300 MG, 1 capsule, Orally, Three times a day, 100 days, 300 Capsule, Refills 3.  <br/>Notes: Continue diabetic management, monitor labs.  </td></tr><tr><td/></tr><tr><td><span class="bold">6. Type 2 diabetes mellitus with other specified complication, without long-term current use of insulin</span> <br/>Continue metFORMIN HCl Tablet, 500 MG, 1 tablet with a meal, Orally, Twice a day.  <br/>Notes: Diabetes with hyperlipidemia.  <br/>Clinical Notes: Diabetes with hyperlipidemia.  </td></tr><tr><td/></tr><tr><td><span class="bold">7. Chronic atrial fibrillation</span> <br/>Notes: Continue medication therapy, follow up with cardiology. Anticoagulation not indicated due to Watchman procedure  </td></tr><tr><td/></tr><tr><td><span class="bold">8. Presence of Watchman left atrial appendage closure device</span> <br/>Notes: Patient s/p closure of left atrial appendage, anticoagulation no longer required.  </td></tr><tr><td/></tr><tr><td><span class="bold">9. HISTORY OF VENTRICULAR TACHYCARDIA</span> <br/>Notes: S/p cardiac ablation with ICD in place, follow up with cardiology/EPS  </td></tr><tr><td/></tr><tr><td><span class="bold">10. Presence of biventricular implantable cardioverter-defibrillator (ICD)</span> <br/>Notes: Follow up with cardiology/EPS  </td></tr><tr><td/></tr><tr><td><span class="bold">11. History of cardiac radiofrequency ablation</span> <br/>Notes: Follow up with cardiology/EPS  </td></tr><tr><td/></tr><tr><td><span class="bold">12. Coronary artery disease involving native coronary artery of native heart without angina pectoris</span> <br/>Continue Aspirin Tablet Delayed Release, 81 MG, 1 tablet, Orally, Once a day.  <br/>Notes: Continue medication managment, follow up with cardiology  </td></tr><tr><td/></tr><tr><td><span class="bold">13. S/P coronary artery stent placement</span> <br/>Notes: Continue medication managment, follow up with cardiology  </td></tr><tr><td/></tr><tr><td><span class="bold">14. Ischemic cardiomyopathy</span> <br/>Notes: Continue medication managment, follow up with cardiology  </td></tr><tr><td/></tr><tr><td><span class="bold">15. Hyperlipidemia, unspecified hyperlipidemia type</span> <br/>Continue Atorvastatin Calcium Tablet, 80 MG, 1 tablet, Orally, Once a day, 100 days, 100 Tablet, Refills 3.  <br/>     <span class="Underline">LAB: Lipid Panel With LDL/HDL Ratio-235010 (Ordered for [REDACTED])</span></td></tr><tr><td/></tr><tr><td><span class="bold">16. Anemia in chronic kidney disease</span> <br/>Refill Ferrous Gluconate Tablet, 324 (38 Fe) MG, 1 tablet, Orally, Once a day, 90 days, 90 Tablet, Refills 1.  <br/>     <span class="Underline">LAB: Ferritin-004598 (Ordered for [REDACTED])</span><br/>     <span class="Underline">LAB: Iron and TIBC-001321 (Ordered for [REDACTED])</span><br/>     <span class="Underline">LAB: Vitamin B12 and Folate-000810 (Ordered for [REDACTED])</span><br/>Notes: Monitor CBC, being treated with iron infusions by hematology  </td></tr><tr><td/></tr><tr><td><span class="bold">17. Centrilobular emphysema</span> <br/>Continue Ventolin HFA Aerosol Solution, 108 (90 Base) MCG/ACT, Inhalation.  <br/>Notes: Continue use of inhaler PRN  </td></tr><tr><td/></tr><tr><td><span class="bold">18. Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene, without long-term current use of insulin</span> <br/>Notes: Continue diabetic management, monitor labs.  <br/>Clinical Notes: Continue aspirin, statin therapy and blood pressure control  </td></tr><tr><td/></tr><tr><td><span class="bold">19. HISTORY OF GOUT</span> <br/>Continue Allopurinol Tablet, 100 MG, 1 tablet, Orally, Once a day.  </td></tr><tr><td/></tr><tr><td><span class="bold">20. Schizophrenia, unspecified type</span> <br/>Notes: Condition currently stable, not requiring treatment. Continue to monitor.  </td></tr><tr><td/></tr><tr><td><span class="bold">21. SECONDARY HYPERPARATHYROIDISM, RENAL</span> <br/>Notes: PTH level elevated with normal calcium level, continue to monitor  </td></tr><tr><td/></tr><tr><td><span class="bold">22. HISTORY OF SUBSTANCE ABUSE</span> <br/>Notes: Remains abstinent from drug use  </td></tr><tr><td/></tr><tr><td><span class="bold">23. Lung fibrosis</span> <br/>Notes: Fibrosis of lungs noted on prior CT scan. Patient is asymptomatic, and treatment not indicated.  </td></tr><tr><td/></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Procedure Codes:</span> G8420 BMI&lt;30 AND &gt;=22 CALC &amp; DOCU3078F DIAST BP &lt; 80 MM HG3074F SYST BP LT 130 MM HGG8473 ACE/ARB THXPY RX'D3044F HG A1C LEVEL LT 7.0%3048F LDL-C &lt;100 MG/DL3060F POS MICROALBUMINURIA REV82570 ASSAY OF URINE CREATININEG8450 BETA-BLOC RX PT W/ABN LVEF4013F STATIN THERAPY/CURRENTLY TKN</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Preventive Medicine:</span> <br/>  Preventative Medicine: Depression Screening Date Completed:[REDACTED]. COA Date Completed: [REDACTED]. Colorectal Screening Date Completed: [REDACTED]. </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Follow Up:</span> 3 Months,prn</td></tr></tbody></table></li></ul><ul><li/></ul><br/><content><span class="bold">Billing  Information:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content><span class="bold">Visit Code:</span></content> <br/>99214 Office Visit, Est Pt., Level 4.  </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content><span class="bold">Procedure Codes:</span></content> <br/>G8420 BMI&lt;30 AND &gt;=22 CALC &amp; DOCU. <br/>3078F DIAST BP &lt; 80 MM HG. <br/>3074F SYST BP LT 130 MM HG. <br/>G8473 ACE/ARB THXPY RX'D. <br/>3044F HG A1C LEVEL LT 7.0%. <br/>3048F LDL-C &lt;100 MG/DL. <br/>3060F POS MICROALBUMINURIA REV. <br/>82570 ASSAY OF URINE CREATININE. <br/>G8450 BETA-BLOC RX PT W/ABN LVEF. <br/>4013F STATIN THERAPY/CURRENTLY TKN. </td></tr></tbody></table></li></ul><br/><tr><td valign="top"><span class="bold">Care Plan Details</span><ul><li><table cellpadding="1" cellspacing="0" border="1"><tbody/></table></li></ul></td></tr><ul><li><table width="100%" border="0"><tbody><tr><td/></tr><tr><td valign="top"/></tr><tr><td/></tr><tr><td/></tr><tr><td valign="top">Electronically signed by [REDACTED] , MD, ME91599  on [REDACTED] 03:59 PM EDT</td></tr><tr><td valign="top">Sign off status: Completed</td></tr><tr><td/></tr></tbody></table></li></ul><span class="content_span">true</span></td></tr></tbody><tbody><tr><td><br/><ul><li><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td align="left"><span class="bold">Provider:</span> [REDACTED], MD</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td/><td align="right"><span class="content_span">Generated for Printing/Faxing/eTransmitting on: [REDACTED] 07:27 PM EDT</span></td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></div><h3><a name="id10" href="#toc">History and Physical Notes</a></h3><div><ul><li><p>Physical Examination</p><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th></tr></thead><tbody><tr><td>GENERAL</td><td>-</td><td colspan="2">well-appearing, well-developed, no acute distress</td></tr><tr><td>HEENT</td><td>-</td><td colspan="2">PERRLA, EOMI, no palor or icterus</td></tr><tr><td>NECK</td><td>-</td><td colspan="2">no JVD, no lymphadenopathy, no thyroidomegaly, no carotid bruit</td></tr><tr><td>HEART</td><td>-</td><td colspan="2">Regular rhytm, S1S2 normal</td></tr><tr><td>ABDOMEN</td><td>-</td><td colspan="2">Soft, non tender, not disended, BS +, no organomegaly</td></tr><tr><td>NEUROLOGY</td><td>-</td><td colspan="2">Conscious, AAO x 3, no new focal deficits</td></tr><tr><td>EXTREMITIES</td><td>-</td><td colspan="2">No cyanosis, clubbing or edema</td></tr><tr><td>SKIN</td><td>-</td><td colspan="2">normal turgor and texture</td></tr><tr><td>Chest</td><td>-</td><td colspan="2">Symmetric with normal chest wall movement</td></tr></tbody></table><br/></li></ul></div><br/><br/>
</body></html>